Skip to main content
OpenTrials
Completed

NCT Number: NCT03489226

Capsimax Effect on Metabolic Rate, Satiety and Food Intake

Comparison of Capsimax™ 2mg and 4mg of capsicum extract vs. placebo on metabolic rate and satiety.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Pennington Biomedical Research Center

Baton Rouge, Louisiana, 70808, United States

About this study

Capsimax™ is a capsicum extract in a bead technology to avoid oral and gastric burning. Capsimax™ 2mg, Capsimax™ 4 mg and placebo was initially given as a single dose on an empty stomach with measures of metabolic rate, and satiety before and after and food intake at 1 hour after Capsimax™.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • BMI between 25 and 40 kg/m2 inclusive
  • Healthy
  • If of child-bearing potential, use of effective contraception

Exclusion criteria

Subjects excluded will:

  • Have received an investigational product in another trial within 30 days of enrollment.
  • Have lost 10 or more pounds in the 3 months prior to randomization and maintained the weight loss.
  • Use tobacco products
  • Use a nicotine patch or gum.
  • Take regular medication other than oral contraceptives or estrogen replacement therapy.
  • Take products containing ephedra or medications known to increase metabolic rate like stimulants taken for attention deficit disorder.
  • Not eat at regular mealtimes.
  • Have a history of alcohol or drug abuse in the past year.
  • Nurse a baby or be a member of a vulnerable population including adults unable to consent, pregnant women, prisoners or minors.
  • Have a clinically significant history of diabetes, high blood pressure (>140/90), thyroid disease, heart disease, kidney disease or liver disease.
  • Have a known allergy to capsaicin caffeine, piperine or niacin.
  • Have clinically significant laboratory findings in the opinion of the investigator.
  • Score greater than 13 on the restraint scale of the 3-factor eating questionnaire.

Treatment and study plan

Capsimax

Dietary Supplement

Capsimax

Placebo

Dietary Supplement

Placebo

Meal

Other

Meal

Primary outcomes

  1. Resting Metabolic Rate

    Time frame: up to 5 hours

    Metabolic cart measurement difference before and after intervention

Secondary outcomes

  1. Satiety by Visual Analog Scale (hunger, fullness, prospective food intake and satisfaction)

    Time frame: Baseline to 4 hours

    Difference in area under the curve from baseline of the Mean Visual Analog. Each question on the scale ranges from 0 to 100 mm. The two ends of the scale are anchored by the highest and lowest values (e.g. "the hungriest I have ever been" to "no hunger at all"). Some questions have high values on the right and others have high values on the left. Each question (hunger, fullness, prospective food intake and satisfaction) is a sub-scale. Each sub-scale is scored separately.

  2. Food Intake

    Time frame: 1 hour after intervention

    Meal with unlimited portions

Sponsors and collaborators

Lead sponsor

Pennington Biomedical Research Center

Other

Collaborators

  • OmniActive Health Technologies

Registry information

Official study title

A Pilot Study of the Effect of a Dietary Herbal Supplement Containing Capsaicin or Placebo on Satiety, Metabolic Rate and Food Intake in Healthy Adults.

Important dates

Study start
2016
Primary completion
2017
Study completion
2017
First posted
Apr 5, 2018
Registry last updated
Aug 31, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.